drugset / Trial / NCT02206087
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin
RandomizedSequentialSingle-blindOther
Summary
Normal subjects will receive unfractionated heparin followed by a single dose of PER977 with dose escalation by cohort. Ten subjects enrolled in Cohort 4 will receive a single dose of PER977 followed by a one-week washout and then will receive unfractionated heparin followed by a single dose of PER977. The study will provide some insight into the doses that may be required to reverse anticoagulation induced by heparin.
Timeline
- Start
- 2014-06
- Primary completion
- 2016-03
- Completion
- 2016-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ciraparantag | Small molecule | 100 mg | — |
| Subject | Ciraparantag | Small molecule | 200 mg | — |
| Subject | Ciraparantag | Small molecule | 300 mg | — |
| Subject | Ciraparantag | Small molecule | 400 mg | — |
| Subject | Ciraparantag | Small molecule | 500 mg | — |
| Subject | Ciraparantag | Small molecule | 600 mg | — |
| Background | Heparin | Other / unclassified | — | — |
Indications
No indication recorded.